Induced pluripotent stem cells (Ipscs) and gene therapy: A new era for the treatment of neurological diseases

Giulia Paolini Sguazzi, Valentina Muto, Marco Tartaglia, Enrico Bertini, Claudia Compagnucci

Research output: Contribution to journalReview articlepeer-review


To date, gene therapy has employed viral vectors to deliver therapeutic genes. However, recent progress in molecular and cell biology has revolutionized the field of stem cells and gene therapy. A few years ago, clinical trials started using stem cell replacement therapy, and the induced pluripotent stem cells (iPSCs) technology combined with CRISPR‐Cas9 gene editing has launched a new era in gene therapy for the treatment of neurological disorders. Here, we summarize the latest findings in this research field and discuss their clinical applications, emphasizing the relevance of recent studies in the development of innovative stem cell and gene editing therapeutic approaches. Even though tumorigenicity and immunogenicity are existing hurdles, we report how recent progress has tackled them, making engineered stem cell transplantation therapy a realistic option.

Original languageEnglish
Article number13674
JournalInternational Journal of Molecular Sciences
Issue number24
Publication statusPublished - Dec 1 2021


  • CRISPR‐Cas9 gene editing
  • Gene therapy
  • IPSCs
  • Neurodegeneration
  • Non‐viral vector
  • Pediatric diseases
  • Stem cells
  • Viral vector

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Induced pluripotent stem cells (Ipscs) and gene therapy: A new era for the treatment of neurological diseases'. Together they form a unique fingerprint.

Cite this